(TEM) Tempus AI, Common Stock - Overview

Sector: Healthcare | Industry: Health Information Services | Exchange: NASDAQ (USA) | Market Cap: 9.063m USD | Total Return: -20.5% in 12m

Genetic Testing, Data Analytics, Clinical Trials, Precision Medicine
Total Rating 16
Safety 34
Buy Signal -0.33
Health Information Services
Industry Rotation: +9.7
Market Cap: 9.06B
Avg Turnover: 268M
Risk 3d forecast
Volatility68.6%
VaR 5th Pctl11.3%
VaR vs Median0.15%
Reward TTM
Sharpe Ratio0.13
Rel. Str. IBD8.3
Rel. Str. Peer Group15
Character TTM
Beta3.829
Beta Downside3.496
Hurst Exponent0.545
Drawdowns 3y
Max DD58.99%
CAGR/Max DD0.21
CAGR/Mean DD0.39
EPS (Earnings per Share) EPS (Earnings per Share) of TEM over the last years for every Quarter: "2021-06": null, "2021-09": null, "2021-12": null, "2022-12": null, "2023-03": null, "2023-06": null, "2023-09": null, "2023-12": null, "2024-03": -0.98, "2024-06": -0.63, "2024-09": -0.25, "2024-12": -0.18, "2025-03": -0.24, "2025-06": -0.22, "2025-09": -0.46, "2025-12": -0.04, "2026-03": -0.13,
Last SUE: 0.10
Qual. Beats: 0
Revenue Revenue of TEM over the last years for every Quarter: 2021-06: 66.0475, 2021-09: 52.448, 2021-12: 73.31, 2022-12: 100.626, 2023-03: 115.624, 2023-06: 132.417, 2023-09: 136.057, 2023-12: 147.724, 2024-03: 145.82, 2024-06: 165.969, 2024-09: 180.929, 2024-12: 200.68, 2025-03: 255.737, 2025-06: 314.635, 2025-09: 334.206, 2025-12: 367.211, 2026-03: 348.116,
Rev. CAGR: 52.82%
Rev. Trend: 98.7%
Last SUE: 0.44
Qual. Beats: 0

Warnings

Interest Coverage Ratio -1.4 is critical

Altman Z'' -3.90 < 1.0 - financial distress zone

Tailwinds

No distinct edge detected

Description: TEM Tempus AI, Common Stock

Tempus AI, Inc. (TEM) is a healthcare technology firm specializing in precision medicine through the integration of artificial intelligence and multimodal data. The company operates a proprietary platform that connects clinical diagnostics with data analytics, offering genomic profiling, molecular pathology tests, and pharmacogenomic testing for psychiatric conditions. Its business model relies on a closed-loop system where diagnostic laboratory results feed into a vast repository of clinical and imaging data to inform physician decision-making and pharmaceutical research.

The company serves the Life Sciences Tools & Services sector, providing software applications like Lens for advanced research and Insights for licensing de-identified data libraries to biopharmaceutical partners. Tempus maintains strategic collaborations with major industry players, including AstraZeneca, GSK, and Merck, to facilitate clinical trial matching and drug discovery. Unlike traditional diagnostic labs, Tempus utilizes biological modeling through tumor-derived organoids and AI-driven algorithms to predict patient responses to specific therapies.

For a deeper look into the companys valuation metrics and long-term growth potential, consider reviewing the latest data on ValueRay. This comprehensive approach to data integration positions the company at the intersection of high-throughput diagnostics and software-as-a-service (SaaS) within the evolving precision oncology market.

Headlines to Watch Out For
  • Data licensing revenue growth from life sciences and pharmaceutical partnerships
  • Expansion of NGS diagnostic testing volume across oncology and psychiatry sectors
  • High research and development costs delaying pathway to GAAP profitability
  • Integration of AI-driven clinical trial matching services for drug developers
  • Regulatory shifts in FDA oversight of laboratory developed tests and diagnostics
Piotroski VR-10 (Strict) 2.5
Net Income: -302.9m TTM > 0 and > 6% of Revenue
FCF/TA: -0.10 > 0.02 and ΔFCF/TA 3.64 > 1.0
NWC/Revenue: 53.95% < 20% (prev 29.56%; Δ 24.39% < -1%)
CFO/TA -0.09 > 3% & CFO -185.7m > Net Income -302.9m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 3.31 > 1.5 & < 3
Outstanding Shares: last quarter (179.0m) vs 12m ago 4.96% < -2%
Gross Margin: 69.55% > 18% (prev 0.57%; Δ 6.90k% > 0.5%)
Asset Turnover: 74.18% > 50% (prev 52.06%; Δ 22.12% > 0%)
Interest Coverage Ratio: -1.39 > 6 (EBITDA TTM -199.5m / Interest Expense TTM 151.2m)
Altman Z'' -3.90
A: 0.34 (Total Current Assets 1.05b - Total Current Liabilities 318.0m) / Total Assets 2.14b
B: -1.18 (Retained Earnings -2.52b / Total Assets 2.14b)
C: -0.11 (EBIT TTM -209.4m / Avg Total Assets 1.84b)
D: -1.47 (Book Value of Equity -2.52b / Total Liabilities 1.72b)
Altman-Z'' = -3.90 = D
Beneish M -3.11
DSRI: 0.69 (Receivables 308.6m/262.6m, Revenue 1.36b/803.3m)
GMI: 0.82 (GM 69.55% / 57.09%)
AQI: 0.80 (AQ_t 0.44 / AQ_t-1 0.54)
SGI: 1.70 (Revenue 1.36b / 803.3m)
TATA: -0.05 (NI -302.9m - CFO -185.7m) / TA 2.14b)
Beneish M = -3.11 (Cap -4..+1) = AA
What is the price of TEM shares?

As of June 01, 2026, the stock is trading at USD 50.47 with a total of 11,482,568 shares traded.
Over the past week, the price has changed by +8.56%, over one month by -9.03%, over three months by -5.33% and over the past year by -20.48%.

Is TEM a buy, sell or hold?

Tempus AI, Common Stock has received a consensus analysts rating of 3.83. Therefore, it is recommended to buy TEM.

  • StrongBuy: 4
  • Buy: 2
  • Hold: 6
  • Sell: 0
  • StrongSell: 0

What are the forecasts/targets for the TEM price?
Analysts Target Price 67.2 33.1%
Tempus AI, Common Stock (TEM) - Fundamental Data Overview as of 31 May 2026
Market Cap USD = 9.06b (9.06b USD * 1.0 USD.USD)
P/S = 6.6433
P/B = 21.764
Revenue TTM = 1.36b USD
EBIT TTM = -209.4m USD
EBITDA TTM = -199.5m USD
Long Term Debt = 1.23b USD (from longTermDebt, last quarter)
Short Term Debt = 12.6m USD (from shortTermDebt, last quarter)
Debt = 1.33b USD (corrected: LT Debt 1.23b + ST Debt 12.6m) + Leases 85.4m
Net Debt = 692.1m USD (calculated: Debt 1.33b - CCE 639.1m)
Enterprise Value = 9.75b USD (9.06b + Debt 1.33b - CCE 639.1m)
Interest Coverage Ratio = -1.39 (Ebit TTM -209.4m / Interest Expense TTM 151.2m)
EV/FCF = -45.06x (Enterprise Value 9.75b / FCF TTM -216.5m)
FCF Yield = -2.22% (FCF TTM -216.5m / Enterprise Value 9.75b)
FCF Margin = -15.87% (FCF TTM -216.5m / Revenue TTM 1.36b)
Net Margin = -22.20% (Net Income TTM -302.9m / Revenue TTM 1.36b)
Gross Margin = 69.55% ((Revenue TTM 1.36b - Cost of Revenue TTM 415.3m) / Revenue TTM)
Gross Margin QoQ = 62.72% (prev 89.74%)
Tobins Q-Ratio = 4.57 (Enterprise Value 9.75b / Total Assets 2.14b)
Interest Expense / Debt = 11.36% (Interest Expense 151.2m / Debt 1.33b)
Taxrate = 21.0% (US default 21%)
NOPAT = -165.4m (EBIT -209.4m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 3.31 (Total Current Assets 1.05b / Total Current Liabilities 318.0m)
Debt / Equity = 3.20 (Debt 1.33b / totalStockholderEquity, last quarter 416.4m)
 Debt / EBITDA = -3.47 (negative EBITDA) (Net Debt 692.1m / EBITDA -199.5m)
 Debt / FCF = -3.20 (negative FCF - burning cash) (Net Debt 692.1m / FCF TTM -216.5m)
 Total Stockholder Equity = 431.3m (last 4 quarters mean from totalStockholderEquity)
RoA = -16.47% (Net Income -302.9m / Total Assets 2.14b)
RoE = -10.26% (Net Income TTM -302.9m / Total Stockholder Equity 2.95b)
RoCE = -5.00% (EBIT -209.4m / Capital Employed (Equity 2.95b + L.T.Debt 1.23b))
 RoIC = -13.90% (negative operating profit) (NOPAT -165.4m / Invested Capital 1.19b)
 WACC = 18.11% (E(9.06b)/V(10.4b) * Re(19.45%) + D(1.33b)/V(10.4b) * Rd(11.36%) * (1-Tc(0.21)))
Discount Rate = 19.45% (= CAPM, Blume Beta Adj.) -> capped to 13.17%
Shares (quarterly) Correlation: 89.89 | Cagr: 59.06%
 [DCF] Fair Price = unknown (Cash Flow -216.5m)
 EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.10 | # QB: 0
Revenue Correlation: 98.74 | Revenue CAGR: 52.82% | SUE: 0.44 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.16 | Chg30d=-7.35% | Revisions=-20% | Analysts=12
EPS next Quarter (2026-09-30): EPS=-0.11 | Chg30d=-20.74% | Revisions=-20% | Analysts=12
EPS current Year (2026-12-31): EPS=-0.41 | Chg30d=+7.29% | Revisions=+47% | GrowthEPS=+32.2% | GrowthRev=+25.3%
EPS next Year (2027-12-31): EPS=-0.14 | Chg30d=-52.10% | Revisions=+0% | GrowthEPS=+66.7% | GrowthRev=+21.9%
[Analyst] Revisions Ratio: +47%